Medicines360 is proud to make an important announcement about LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
CLICK HERE TO READ THE PRESS RELEASE
Women should have access to the medicines they need to live their best and fullest lives. Medicines360 is helping in a unique way.
OUR MISSIONDirect Relief’s Kirchmaier Volunteer Center was standing room only Friday morning, March 8, as more than 150 people gathered in honor of International Women’s Day to celebrate achievements and acknowledge remaining hurdles, including the lack of global access to affordable maternal health care. This year’s theme was “balance for better — the better the balance, […]
Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]
Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.
We’re reinventing the pharma business model: we identify areas in women’s health where patients face limited choices, develop medicines that expand women’s options and make them available in ways that close gaps in access.
We believe women should have access to medicines, regardless of their diverse needs. As we choose products for development and study them in robust clinical trials, we tackle areas where many women struggle with limited medicine choices.
PRODUCTS & PIPELINE